Global X SuperDividend ETF vs Stryker Corporation — how do they compare? Global X SuperDividend ETF trades at $23.96 (market cap $1.17B), while Stryker Corporation trades at $277.33 (market cap $106.24B). The key difference: Stryker Corporation is far larger — about 90.8× Global X SuperDividend ETF's market cap, and Stryker Corporation pays a 1.27% dividend while Global X SuperDividend ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Global X SuperDividend ETF for 47 Days and Stryker Corporation for 21 Days on average.
| SDIV | SYK | |
|---|---|---|
Market Cap | $1.17B | $106.24B |
Volume | 387,692 | 2,982,001 |
Sector | Broad Market / Factor | Health |
52-Week High | $26.34 | $388.35 |
52-Week Low | $22.90 | $269.75 |
Typical Hold Time | 47 Days | 21 Days |
Enterprise Value | — | $117.70B |
Dividend Yield | — | 1.27% |
Signals from Pluang's Aura AI — not financial advice
SDIV trades at $23.96, up 1.61% with a bearish technical outlook from moving averages. The ETF maintains an 8%+ dividend yield but faces significant price erosion, having lost 66% since inception according to Seeking Alpha (2026-09-11). Recent institutional buying includes Ameritas Advisory Services increasing its position by 92.6% in Q2 2026. Technical indicators show mixed signals with neutral oscillators but bearish moving averages and ADX readings.
SDIV offers high income potential but carries substantial principal risk. The fund's deep value approach lacks quality screening, leading to persistent underperformance versus global benchmarks. While monthly dividends attract income seekers, the erosion of capital requires careful risk assessment for long-term investors considering this high-yield strategy.
Stryker (SYK) trades at $277.33, up 0.7% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bearish technical signal with key support at $274 and resistance at $279, while fundamentals remain solid with a 14.43% net income margin and strong analyst consensus. Recent news highlights ongoing legal scrutiny related to a manufacturing issue disclosed in September 2026, which caused an 8.8% stock drop, but the company continues to innovate with product launches like Prophecy surgical planning.
The outlook for SYK is cautiously optimistic, with a consensus price target of $368.11 implying significant upside. Investment opportunities include robust profitability and growth in medical technology, but risks persist from legal investigations and potential operational disruptions. Investors should weigh strong analyst support against near-term sentiment headwinds.
Trailing returns across standard periods
Latest headlines on both assets
SDIV is an ETF that invests in 100 of the highest dividend-yielding equity securities in the world. The fund seeks to provide a high level of income to investors by selecting companies from both developed and emerging markets that have historically provided high dividend yields. By diversifying globally, SDIV aims to mitigate risks associated with focusing on a single country, while offering monthly distributions to its shareholders.
Read more on SDIV →Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →